Figure 5

Urinary N-telopeptide/urinary creatinine ratio (uNTX/uCr) in girls ( upper panel ) and in boys ( lower panel ). Data is shown for each individual patient prior to the first intravenous pamidronate treatment (IVP); just after the first IVP; at the time of pamidronate discontinuation; and either at the time of last follow-up for patients who did not flare or at the time of CRMO flare. Continuous lines represent the 75^th (top), 50^th (middle), and 25^th (bottom) percentile, respectively, of the reference range for healthy subjects [24].